Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Major Depressive Disorder

Treatments: Drug: aprepitant; Drug: Comparator: paroxetine HCL

Study type: Interventional

Funder types: Industry

Identifiers

NCT00034983

MK0869-066

0869-066

2006_407

Formally-497B

Details and patient eligibility

About

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression

Full description

The duration of treatment is 1 year.

Enrollment: 900 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Major Depressive Disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind